Search

Your search keyword '"Devika Ashok"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Devika Ashok" Remove constraint Author: "Devika Ashok" Database OpenAIRE Remove constraint Database: OpenAIRE
17 results on '"Devika Ashok"'

Search Results

1. Abstract A10: The dual A2aR/A2bR antagonist AB928 reverses adenosine-mediated immune suppression and inhibits tumor growth in vivo

2. Magnetically recoverable Ir/IrO2@Fe3O4 core/ SiO2 shell catalyst for the reduction of organic pollutants in water

Catalog

Books, media, physical & digital resources

3. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

4. Establishment and Characterization of a Functionally Competent Type 2 Conventional Dendritic Cell Line

5. Activated group 3 innate lymphoid cells promote T-cell–mediated immune responses

6. Cross-presenting dendritic cells are required for control ofLeishmania majorinfection

7. Abstract 4100: Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy

8. Abstract 3168: Methods for assessment of the 'adenosine fingerprint' in clinical trials of AB928

9. Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers

10. AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies

11. Abstract A157: Preclinical pharmacokinetic and pharmacodynamic characterization of AB680, a small-molecule CD73 inhibitor for cancer immunotherapy

12. Cross-presenting dendritic cells are required for control of Leishmania major infection

13. Derivation and Utilization of Functional CD8(+) Dendritic Cell Lines

14. Abstract 3769: Pharmacokinetic-pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors

15. Derivation and Utilization of Functional CD8+ Dendritic Cell Lines

16. Abstract 1302: High complexity flow cytometry panels to monitor target expression, T-cell activation and suppresssion by novel immunotherapies in hematomalignancy clinical trials

17. Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research